MoonLake Immunotherapeutics (MLTX)
USD 52.25
(-7.19%)
USD 52.25
(-7.19%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -42.77 Million | -55.89 Million | -35.17 Million | -316.69 Thousand |
| Net Income | -36 Million | -64.5 Million | -53.64 Million | -90.83 Thousand |
| Depreciation & Amortization | 13.15 Thousand | 12.35 Thousand | 4971.00 | - |
| Deferred income taxes | -7.97 Million | - | 1.39 Million | - |
| Stock-based compensation | 7.1 Million | 9654.78 | 10.86 Thousand | - |
| Change in working capital | -6.21 Million | -1.42 Million | 4.48 Million | -215.93 Thousand |
| Other non-cash items | 299.7 Thousand | 372.48 Thousand | 12.56 Million | -9917.00 |
| Investing Cash Flow | -25.18 Million | -32.34 Million | -50.71 Thousand | -115 Million |
| Investments in PPE | -284.63 Thousand | -16 Thousand | -50.71 Thousand | - |
| Acquisitions | 24.89 Thousand | 32.32 Thousand | - | - |
| Investment purchases | -175.73 Million | -42.22 Million | - | -115 Million |
| Sales/Maturities of investments | 150.83 Million | 9.9 Million | - | - |
| Other Investing Activities | -24.89 Thousand | -32.32 Thousand | - | - |
| Financing Cash Flow | 479.7 Million | 119.69 Million | 43.26 Million | 116.65 Million |
| Debt repayment | - | -15 Million | -15 Million | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | -6202.00 | - |
| Common Stock Issuance | 482.45 Million | 3791.00 | 28.26 Million | 117 Million |
| Other Financing Activities | -2.75 Million | 134.68 Million | 51.92 Thousand | -347.38 Thousand |
| Accounts receivables | -839.73 Thousand | -68.35 Thousand | -148.77 Thousand | - |
| Accounts payables | - | -1.31 Million | 1.56 Million | - |
| Inventory | - | - | - | - |
| Other working capital | -5.37 Million | -44.79 Thousand | 3.06 Million | -215.93 Thousand |
| Cash at beginning of period | 39.5 Million | 8.03 Million | 1.33 Million | - |
| Cash at end of period | 451.16 Million | 39.5 Million | 8.03 Million | 1.33 Million |
| Capital Expenditure | -284.63 Thousand | -16 Thousand | -50.71 Thousand | - |
| Effect of forex changes on cash | -75.3 Thousand | 8540.00 | 2.25 | - |
| Net cash flow / Change in cash | 411.66 Million | 31.46 Million | 6.7 Million | 1.33 Million |
| Free Cash Flow | -43.06 Million | -55.9 Million | -35.22 Million | -316.69 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -24.26 Million | -13.67 Million | -36 Million | -7.43 Million | -11.61 Million | -12.35 Million |
| Depreciation & Amortization | 28.11 Thousand | 22.81 Thousand | 13.15 Thousand | 3289.00 | 3290.00 | 3289.00 |
| Deferred income taxes | - | - | -7.97 Million | 37.46 Thousand | -23.96 Thousand | -13.5 Thousand |
| Stock-based compensation | 1.82 Million | 1.67 Million | 7106.01 | 1.6 Million | 1.42 Million | 1.49 Million |
| Change in working capital | -5.32 Million | -2.84 Million | -6.21 Million | -6.53 Million | 1.01 Million | -1.25 Million |
| Other non-cash items | 1.9 Million | 2.03 Million | 299.7 Thousand | -16.06 Thousand | -46.99 Thousand | -33.28 Thousand |
| Investing Cash Flow | -87.74 Million | -28.8 Million | -25.18 Million | 116.86 Million | -174.37 Million | 12.67 Million |
| Investments in PPE | 3.00 | -211.76 Thousand | -284.63 Thousand | -284.63 Thousand | - | - |
| Acquisitions | - | - | 24.89 Thousand | - | - | - |
| Investment purchases | -86.44 Million | -87.71 Million | -175.73 Million | -175.55 Billion | -175.73 Million | - |
| Sales/Maturities of investments | -1.3 Million | 59.12 Million | 150.83 Million | 117.15 Million | 1.35 Million | 12.67 Million |
| Other Investing Activities | -87.74 Million | -28.59 Million | -24.89 Thousand | 175.55 Billion | -174.37 Thousand | 12.67 Thousand |
| Financing Cash Flow | - | 50.97 Million | 479.7 Million | 28.41 Million | - | 451.28 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -50.00 | - | - | - | - |
| Common Stock Issuance | - | 52.54 Million | 482.45 Million | 31.16 Million | - | 451.28 Million |
| Other Financing Activities | - | -1.56 Million | -2.75 Million | -2.75 Million | - | 451.28 Thousand |
| Accounts receivables | -180.93 Thousand | -439.01 Thousand | -839.73 Thousand | -336.1 Thousand | -100.98 Thousand | -241.32 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -5.14 Million | -2.4 Million | -5.37 Million | -6.2 Million | 1.11 Million | -1.01 Million |
| Cash at beginning of period | 458.44 Million | 451.16 Million | 39.5 Million | 318.16 Million | 501.78 Million | 50.12 Million |
| Cash at end of period | 342.79 Million | 458.44 Million | 451.16 Million | 451.16 Million | 318.16 Million | 501.78 Million |
| Capital Expenditure | 3.00 | -211.76 Thousand | -284.63 Thousand | -284.63 Thousand | - | - |
| Effect of forex changes on cash | -16.9 Thousand | 46.47 Thousand | -75.3 Thousand | 64.74 Thousand | 5006.00 | -144.51 Thousand |
| Net cash flow / Change in cash | -115.64 Million | 7.27 Million | 411.66 Million | 133 Million | -183.62 Million | 451.65 Million |
| Free Cash Flow | -27.89 Million | -15.16 Million | -43.06 Million | -12.62 Million | -9.25 Million | -12.15 Million |
7723
AMSWA
GLITTEKG
NINTF
SGR-UN
CCOI